Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director

Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director. Ascend Advanced Therapies (Ascend) Canada France Germany Spain United States of America United Kingdom Maryland

and investment by EW Healthcare Partners, the Ascend network can support gene therapy, oncolytic, vaccine, immunotherapy, and government customers at all stages of development through to fill/finish," said Flynn. "Process development, optimization, and forthcoming GMP QC capabilities in Munich, Germany are complemented by the GMP facilities in Alachua, Florida, and the company's headquarters in Rockville, MD. This is a world-class offering built to support customers long term."

"We are excited to welcome John and Karen to the board. John and Karen bring tremendous leadership, strategic expertise, and industry knowledge that will help shape the future here," said Mike Stella, CEO of Ascend. "Their counsel and extensive experience will be instrumental as we continue to manufacture advanced therapies and aggressively scale up the capabilities of the Company."

Ascend specializes in high-quality, cost-effective gene therapy development and manufacturing. Following the partnership with EW healthcare Partners that contributed its portfolio company, ABL, Inc. in late 2024, Ascend offers expanded commercial manufacturing, process development, and analytical capabilities across multiple facilities in the U.S. and Europe.

To join us on the Ascend journey, please visit: www.ascend-adv.com or follow us on LinkedIn. To schedule some time to chat, email us at [e-mail].

Ascend Advanced Therapies (Ascend) is a gene to GMP contract development and manufacturing organization (CDMO) specializing in high-quality, cost-effective advanced therapy development and manufacturing. The Company offers expanded commercial facilities and a versatile platform for gene therapies, oncolytics, vaccines and immunotherapies. A collaborative CMC approach backed by therapeutic development roots helps the team guide clients from clinic to commercialization while balancing yield, quality, and cost. Investors include EW Healthcare Partners, Monograph, Abingworth, Petrichor, DCVC Bio, 4BIO Capital, Cathay Health, Anjinomoto, Deerfield, and Digitalis Ventures. Learn more at www.ascend-adv.com.

Logo: https://mma.prnewswire.com/media/2634455/Ascend_ABL_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ascend-advanced-therapies-appoints-john-chiminski-as-chair-and-karen-flynn-as-independent-director-302393225.html